Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy-Reference-Cited by-同舟云学术

Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy

Published:2016-03-23 Issue:1 Volume:119 Page:74-81
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

de la Taille Alexandre¹,Martínez-Piñeiro Luis²,Cabri Patrick³,Houchard Aude³,Schalken Jack⁴,

Affiliation:

1. INSERM U955 Eq07; Department of Urology; CHU Henri Mondor Assistance Publique des Hopitaux de Paris; Créteil France

2. Urology Unit; Infanta Sofía University Hospital; Madrid Spain

3. Ipsen Pharma; Paris France

4. Department of Urology; Radboud University Nijmegen Medical Centre; Nijmegen The Netherlands

Funder

Ipsen Fund

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13455/fullpdf

Reference21 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer;Heidenreich;Eur Urol,2014

3. Leblanc V [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptorelin in patients with metastatic prostate cancer];Abbou;Prog Urol,1997

4. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study;Lundstrom;Clin Drug Investig,2009

5. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer;Martinez-Pineiro;BJU Int,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials;European Urology Oncology;2024-07

2. Lower baseline testosterone level is related to earlier development of castration resistance in metastatic prostate cancer: a multi-center cohort study;Frontiers in Oncology;2024-02-20

3. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy;Japanese Journal of Clinical Oncology;2024-01-20

4. Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis;Current Opinion in Urology;2023-09-25

5. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study;World Journal of Urology;2022-09-04